Learning Hub

iProlepsis project for psoriatic arthritis uses multi-source data analysis for guiding to a novel personalised digital care ecosystem and maximizes the impact. iPROLEPSIS project vision and impact maximisation Health-to-PsA transition through multi-source data analysis guiding to a novel personalised digital care ecosystem and impact maximisation through openness, visibility, networking and reuse of outcomes. Project vision Data analysis, iPROLEPSIS project goals, IoT technologies and mobile application. About Psoriatic Arthritis Psoriatic Arthritis (PsA) is a chronic, inflammatory disease, affecting the peripheral and axial skeleton, with a severe impact on patients’ quality-of-life. It is estimated that 1-2% of the general population has PsA, i.e., 5 to 10 million people in EU are affected . PsA is associated with psoriasis (PsO) and up to 30% of people living with PsO, i.e., at least 100 million people worldwide (WHO), are expected to develop PsA. The goal The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real Worl Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients. Technologies IoT sensing technologies and a mobile application will be at the heart of the RWD collection procedure, while retrospective and prospective multi-source data will be collected from the clinical partners’ databases, combined with open access ones. Through the analysis and visualisation of these data using AI predictive models and an intuitive visual analytics tool, respectively, the iPROLEPSIS will be able to propose personalized treatments (i.e., diet, physical activity, stress/fatigue/pain management), assisting doctors, caregivers, and hospitals towards the optimal management of PsA. Finally, through xAI techniques, iPROLEPSIS aims to facilitate hospitals and policy makers in gaining new insights towards better clinical practices, thus shaping future PsA treatment policies. Impact maximisation To ensure the successful implementation of the pathways towards impact in long-term, the project consortium aims at making iPROLEPSIS a reference for the fight against PsA by: 01 Creating an active iPROLEPSIS community of stakeholders. 02 Informing key stakeholders about results and their clinical innovation potential. 03 Making the outputs widely available for research and business purposes in the long term. 04 Increasing people with/at risk of PsA engagement for addressing their issues and concerns in order to increase their awareness and to build trust into new technology. 05 Reaching similar/relevant R&I projects for promoting networking and joint activities. 06 Establishing a forum/community for HCPs and authorities to develop new guidelines and standards. 07 Identifying exploitation mechanisms and activities, assessing the commercialization and applicability of the concepts and ideas. PROJECT OBJECTIVES

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How will psoriatic arthritis affect me? Sleep and Fatigue See related Handbook section PREVIOUS NEXT

< BACK Seasons Greetings from iPROLEPSIS Dec 20, 2024 Happy holidays and best wishes for the year ahead! As the year comes to a close, we at the iPROLEPSIS consortium wish you warmth, joy, good health, and peace. Your support and engagement mean so much to us. Thank you for being part of our journey! Happy holidays and best wishes for the year ahead! 1/1 PREVIOUS NEXT

< BACK Khalifa University Features iPROLEPSIS in Research News Jun 2, 2025 AI, Apps and Arthritis: A Digital Leap in Psoriatic Care Khalifa University Research News has featured iPROLEPSIS in a new article showcasing our mission to transform psoriatic arthritis care through digital innovation. Led by Prof. Leontios Hadjileontiadis, iPROLEPSIS is a Horizon Europe-funded initiative using artificial intelligence, wearable technology, and mobile health apps to shift care from reactive treatment to proactive prevention . By combining explainable AI with real-world patient data, we aim to support earlier diagnosis , personalized treatment , and patient-centered digital tools that empower both clinicians and individuals living with psoriatic arthritis. Read the full article on Khalifa University website: https://www.ku.ac.ae/ai-apps-and-arthritis-a-digital-leap-in-psoriatic-care Hero section.png Hero section.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 8 Apr 28, 2025 Latest News from iPROLEPSIS Welcome to the eighth edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. iPROLEPSIS project newsletter Issue No. 8_Apr 2025 .pdf Download PDF • 3.38MB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at GRAPPA 2025: Advancing Digital Tools for Psoriatic Arthritis Care Jul 18, 2025 Exploring how digital biomarkers can support hand function assessment in real-world settings iPROLEPSIS participated in the GRAPPA Annual Meeting 2025 , held on 10–12 July in Bogotá, Colombia. Vasilis Charisis (Aristotle University of Thessaloniki – AUTH) presented an overview of the project’s key objectives and emerging results. The talk highlighted how digital biomarkers – captured via smartphone typing dynamics and video-based motor tasks – can support the assessment of hand function in real-world conditions. The session reached approximately 350 stakeholders, including clinicians, researchers, and industry representatives, helping raise awareness of iPROLEPSIS and its goals within the psoriatic disease community. 2.jpg 1.jpg 3.jpg 2.jpg 1/3 PREVIOUS NEXT

< BACK iPROLEPSIS, AI-PROGNOSIS & REBECCA: A Thematic Cluster on AI-Driven Digital Health Jul 17, 2025 Three EU-funded projects exploring real-world data, wearables, and personalised care in healthcare innovation Have you ever asked yourself how to make AI really effective along the patient journey? That was one of the first questions we asked ourselves when we launched our project. Along the way, we discovered we weren’t alone – many other research initiatives working with AI in healthcare were asking the same thing. That’s why we decided to take a step forward and create a cluster : a concrete way to collaborate, foster the impact of our solutions, and improve them through scientific exchange and an open science approach. AI-PROGNOSIS, iPROLEPSIS, and REBECCA – three EU-funded projects to advance patient-centric AI in healthcare. Focusing on Parkinson’s disease (PD), AI-PROGNOSIS is developing a suite of AI-powered tools for both patients and clinicians . These include early risk assessment, symptom monitoring, and medication support – based on real-world data from wearables and patient self-reports. It’s about enabling timely, data-driven decisions and bringing predictive analytics to the heart of primary care. iPROLEPSIS is building a comprehensive digital health ecosystem for psoriatic arthritis (PsA). It brings together a multisource biobank, a smartphone-based app powered by digital biomarkers and AI-driven predictive models, and an intervention module featuring therapeutic games, lifestyle coaching, and sleep support. The goal? To reshape the way we monitor and treat chronic inflammatory diseases through personalised mobile health solutions. Finally, REBECCA is working to improve long-term care for breast cancer survivors. By combining electronic health records with data from wearables and behaviour tracking , it generates real-world evidence on patients’ emotional, functional, and quality-of-life needs. Its explainable AI platform also supports caregivers and families via a dedicated app, empowering a more holistic approach to survivorship. What will we do together? We aim to contribute to the discussion on how AI-based digital health can support medical decision-making and real-time monitoring within daily hospital routines. I ntegrating AI into clinical practice is no easy task. Our solutions are designed to enable real-time health monitoring, informed decision-making, and disease management by leveraging biometric, behavioral, and clinical data –maximizing the impact along the patient journey. Another area of strong interest is the development of digital infrastructures that integrate wearable, clinical, behavioral, and environmental datasets. We believe these can be analyzed collectively through AI to generate real-world evidence and support both predictive and causal modeling – helping to guide research and inform treatment planning in more meaningful ways. Cluster.png Cluster.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at Health Data Summit 2025 Feb 12, 2025 Trustworthy AI in Digital Health iPROLEPSIS is excited to join AI-PROGNOSIS and other Horizon Europe research and innovation projects - T RUSTroke, SmartCHANGE, and STRATIFYHF - at the Health Data Summit 2025 in Brussels. Together, these projects will focus on practical approaches for building trustworthy AI-enabled digital health tools aimed at assessing disease risk and progression. During the workshop titled " Trustworthy AI in Digital Health: From Guidelines to Practice" on 19-20 March 2025, iPROLEPSIS will join experts in discussing the importance of ensuring data quality, addressing bias, and applying ethical AI principles in healthcare solutions. The workshop will cover frameworks, methods, and techniques across the AI system development lifecycle, emphasising how to build AI tools that are robust, fair, transparent, and protect privacy. Key discussion topics include: Ensuring data quality and mitigating bias in AI-driven healthcare Applying ethical AI principles throughout AI system development Balancing fairness, privacy, transparency, and robustness The session will be an opportunity for iPROLEPSIS and its partners to contribute to advancing the responsible use of AI in healthcare and discuss solutions for improving digital health tools. Event details: Health Data Summit 2025 Programme details: Summit Programme 1/1 PREVIOUS NEXT

< BACK Highlights from IEEE MELECON 2024 Jun 28, 2024 Highlights from IEEE MELECON 2024 The iPROLEPSIS breathing games have been presented and well received by the audience at the IEEE MELECON 2024 scientific conference. The conference was held in Porto, Portugal on 25-27 June, 2024. IEEE MELECON 2024 is a major international forum presenting design methodologies, techniques, and experimental results in emerging electro-technologies. It is one of the flagship conferences of the IEEE Region 8 (the largest region of IEEE including Europe, Africa, and Middle East). It is expected to bring together researchers and practitioners from different fields of Electrical Engineering. Read more: IEEE MELECON 2024 – IEEE MELECON 2024 ( ieee-melecon.org ) . 1/5 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the MULTIPULM project kick-off meeting Oct 8, 2025 iPROLEPSIS tools to be adapted for clinical studies in Brazil, Serbia, and Türkiye The iPROLEPSIS project was presented during the kick-off meeting of the MULTIPULM project, held on 29–30 September in Athens. iPROLEPSIS partners Aristotle University of Thessaloniki (AUTH) , Faculdade de Motricidade Humana (FMH) , and Wellics participated in the meeting, which brought together researchers, clinicians, user research experts, and technology providers. Several tools developed within iPROLEPSIS – including the breathing games created by FMH and the biAURA app developed by AUTH – will be further used in MULTIPULM. These tools will be adapted to the local needs of the project’s pilot sites in Brazil, Serbia, and Türkiye, and evaluated in relevant clinical studies. This collaboration demonstrates the adaptability and broader potential of iPROLEPSIS digital tools beyond psoriatic arthritis, supporting research in other chronic conditions. SPBTU_KoM_MULTIPULM_Athens.jpg ae74e3_e25adf83abf6411cace29ed99801554f~mv2.jpg SPBTU_KoM_MULTIPULM_Athens.jpg 1/2 PREVIOUS NEXT

< BACK iPROLEPSIS Research on Digital Rheumatology Published in The Lancet eClinicalMedicine May 19, 2025 New Publication Highlights Explainable AI Tools, Digital Biomarkers, and Multimodal Disease Monitoring for PsA A recent paper published in The Lancet eClinicalMedicine presents the iPROLEPSIS initiative as a comprehensive European research effort aimed at transforming the diagnosis and management of psoriatic arthritis (PsA) through digital innovation and patient-centred care . The paper, titled "European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis", outlines how iPROLEPSIS addresses critical gaps in current PsA care by combining real-world data , wearable sensors , and explainable artificial intelligence (xAI) models. Abstract The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients’ interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem. Read the full paper here: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00175-0/fulltext PIIS2589537025001750 .pdf Download PDF • 1.20MB Lancet publication.png Lancet publication.png 1/1 PREVIOUS NEXT

< BACK Calling for Influencers: Join iPROLEPSIS as an Ambassador for Psoriatic Arthritis Feb 27, 2024 Join the iPROLEPSIS Initiative: Become an Ambassador for the iPROLEPSIS Project Join the iPROLEPSIS initiative! Calling all influencers, psoriatic arthritis warriors and health advocates to become iPROLEPSIS Ambassadors ! Our mission is to shed light upon the health-to-PsA transition through groundbreaking AI-driven analysis and cutting-edge technology. We are creating a digital health ecosystem for personalised psoriatic arthritis risk prediction and management. Are you passionate about health advocacy and psoriatic arthritis awareness? Become an iPROLEPSIS Ambassador and be a part of the change! Here is how you can make a difference as an iPROLEPSIS Ambassador: Promote the iPROLEPSIS mission Share iPROLEPSIS updates and developments Share personal stories and insights Ready to be a part of the change? Contact us at info@iprolepsis.eu , and we will provide you with more details. * Please note that this is voluntary, and no monetary compensation is offered. AI-PROGNOSIS events (8).png AI-PROGNOSIS events (8).png 1/1 PREVIOUS NEXT